Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease; a randomized, double-blind, placebo-controlled study

BMC Medical Genetics

Research Article

Samuel T Henderson¹  Judes Poirier² 

[1] Accera Inc, 380 Interlocken Crescent, Ste 780, 80021, Broomfield, CO, USA;Douglas Institute Research Centre, 6825 Lasalle, H4H 1R3, Verdun, Canada;

关键词: Alzheimer's disease;    ketone bodies;    APOE;    IDE;    IL1B;    insulin;    memory;    cognition;   

DOI  :  10.1186/1471-2350-12-137

 received in 2011-05-31, accepted in 2011-10-12,  发布年份 2011

来源: Springer

【 摘 要 】

BackgroundTo examine the effect of genetic variation in APOE, IDE and IL1B on the response to induced ketosis in the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in subjects with mild to moderate Alzheimer's disease (AD).MethodsGenotype effects on ADAS-Cog scores from a randomized, double-blind, placebo-controlled study in mild to moderate AD were examined by an overall two way analysis of variance. In addition, interactions with the carriage status of the epsilon 4 allele of the APOE gene (APOE4) were examined.ResultsSignificant differences in response to induced ketosis were found among non-carriers of putative gain-of-function polymorphisms in rs1143627 and rs16944 in the IL1B gene and among variants of the polymorphism rs2251101 in the IDE gene. Significant differences were found among non-carriers of the APOE4 gene, with notable improvement among the E3/E3 genotype group.ConclusionsVariants in APOE, IL1B and IDE may influence the cognitive response to induced ketosis in patients with mild to moderate AD.Trial registrationThis trial was registered with ClinicalTrials.gov, registry number NCT00142805.

【 授权许可】

CC BY   
© Henderson and Poirier; licensee BioMed Central Ltd. 2011